1
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Cancer Biology and Therapy

      Submit here by August 31, 2025

      About Cytogenetic and Genome Research: 1.7 Impact Factor I 3.1 CiteScore I 0.385 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      LD-SCLC: Die prognostische Bedeutung des Glasgow Prognostic Score (GPS) für das Überleben nach Radiochemotherapie

      other

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: Established biomarkers for predicting chemoradiotherapy efficacy for limited-disease small cell lung cancer (LD-SCLC) are lacking. The inflammation-based Glasgow Prognostic Score (GPS), comprising serum C-reactive protein (CRP) and albumin levels, can predict survival in advanced cancer. This study investigated whether metabolic and inflammatory markers, including the GPS, can predict the efficacy of chemoradiotherapy in patients with LD-SCLC. Methods: We retrospectively analyzed 124 patients who underwent chemoradiotherapy for LD-SCLC at two institutions between April 2007 and June 2021, and assessed the prognostic significance of various metabolic and inflammatory markers. The GPS was calculated using the CRP and albumin concentrations, and categorized as follows: 0, CRP <1.0 mg/dL and albumin ≥3.5 mg/dL; 1, elevated CRP or decreased albumin; and 2, CRP ≥1.0 mg/dL and albumin<3.5 mg/dL. Differences in progression-free survival (PFS) and overall survival (OS) were examined using Kaplan-Meier curves and Cox proportional-hazard models. Results: The overall response rate was 95.1% (95% confidence interval [CI]: 89.6-97.9%). The median PFS and OS from chemoradiotherapy initiation were 12.6 (95% CI: 9.9-15.4) and 29.0 (95% CI: 24.8-45.5) months, respectively. The GPS demonstrated independent predictive ability for the effectiveness of chemoradiotherapy, wherein favorable scores (GPS 0-1) were significantly correlated with superior PFS and OS compared to unfavorable scores (GPS 2: PFS: 14.8 vs. 6.7 months, p = 0.0001; OS: 35.4 vs. 11.0 months, p < 0.0001).

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

          Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years. We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance. The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period. Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.
            Bookmark
            • Record: found
            • Abstract: not found
            • Book: not found

            Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)

                Bookmark

                Author and article information

                Journal
                KKO
                10.1159/issn.2296-5416
                Kompass Onkologie
                Kompass Onkol
                S. Karger AG
                2296-5416
                2296-5386
                2024
                02 December 2024
                : 11
                : 4
                : 201-202
                Affiliations
                [ ]Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin II, Halle (Saale), Deutschland
                Author notes
                *Susanne Otto, susanne.otto@martha-maria.de
                Article
                542779 Kompass Onkol 2024;11:199–200
                10.1159/000542779
                45db4a40-0871-40cd-804d-826efacb3283
                © 2024 S. Karger GmbH, Freiburg
                History
                Page count
                Pages: 2
                Categories
                Wissenstransfer

                Medicine
                Small cell lung cancer,Limited disease,Chemoradiotherapy,Efficacy,Glasgow Prognostic Score

                Comments

                Comment on this article